Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2026, Vol. 31 ›› Issue (10): 1310-1319.doi: 10.12092/j.issn.1009-2501.2026.10.002

Previous Articles    

Study on the mechanism of Shenshao tablets based on heart-intestinal flora axis in the treatment of chronic heart failure

Qiujin JIA1(), Lu FAN2, Haomin ZHANG2, Xiaoling WANG3, Xiaonan ZHANG2, Peng YUAN2, Yujie HAO3, Wenbao HAN3, Zhuo YUAN2, Yunjiao WANG2, Chao ZHAO4, Shichao LYU2,*()   

  1. 1. Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300250, China
    2. First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine / National Clinical Research Center for Chinese Medicine, Tianjin 300381, China
    3. Qian'an Hospital of Traditional Chinese Medicine, Qian'an 064404, Hebei, China
    4. Shaanxi Institute of International Trade and Commerce, Xi'an 712046, Shaanxi, China
  • Received:2025-07-03 Revised:2025-12-14 Online:2026-10-26 Published:2026-11-11
  • Contact: Shichao LYU E-mail:1261764461@qq.com;dr_lv@foxmail.com

Abstract:

AIM: To investigate the mechanism of Shenshao tablet in treating chronic heart failure (CHF) from the perspective of gut microbiota. METHODS: The CHF model of rat was established by isoproterenol and randomly divided into control, model, low-/high-dose Shenshao tablet, ginseng stem-leaf saponin, and total glucosides of paeony groups. After 4 weeks, cardiac function, myocardial collagen deposition, and intestinal barrier function were assessed. 16S rDNA sequencing and targeted metabolomics were performed. RESULTS: Compared with control group, there were decreased cardiac function, aggravated myocardial fibrosis, and impaired intestinal barrier in the model group. Shenshao tablet reduced LVEDD, LVESD, and NT-proBNP levels, increased LVEF, decreased myocardial collagen deposition, and lowered serum levels of DAO, D-lactate, and endotoxin. Gut microbiota analysis revealed increased abundances of Melainabacteria phylum and Paraprevotella genus, and decreased Actinobacteria phylum in HF rats. Shenshao tablet increased microbial diversity, enriched beneficial bacteria, reduced Spirochaetes phylum abundance, lowered serum trimethylamine N-oxide, and elevated short-chain fatty acids. CONCLUSION: Shenshao tablet ameliorates myocardial remodeling and intestinal barrier dysfunction in chronic heart failure, with effects superior to its individual components. Its cardioprotective mechanism may be associated with the regulation of gut microbiota structure and metabolites.

Key words: Shenshao tablets, gut microbiota, trimethylamine N-oxide

CLC Number: